SCHEMBL16489092

SCHEMBL16489092

N#Cc1cnccc1-c1cncc(C(=O)Nc2ccccc2)n1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 1/20 0.51
ATM Q13315 1/20 0.51
ATR Q13535 1/20 0.51
SCN2A Q99250 3/20 0.46
SCN10A Q9Y5Y9 3/20 0.46
GSK3A P49840 3/20 0.43
GSK3B P49841 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
HTT P42858 1/20 0.42
CNR1 P21554 2/20 0.41
IRAK4 Q9NWZ3 1/20 0.41
GRM4 Q14833 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2486705 0.80 ATR (0.80) PRKDCATMATRCYP3A4
SCHEMBL16420803 0.76 IRAK4 (0.63) ATRSCN2ASCN10AGSK3BMAPT
SCHEMBL20433188 0.75 ATR (0.60) PRKDCATRSCN2ASCN10ASMN1; SMN2
SCHEMBL16489055 0.74 ATR (0.65) PRKDCATRSCN2ASCN10APOLB
SCHEMBL16489061 0.73 ATR (0.62) PRKDCATRSCN2ASCN10ASMN1; SMN2
SCHEMBL18177424 0.70 ATR (0.68) PRKDCATRSCN2ASCN10AIRAK4
SCHEMBL16489052 0.70 ATR (0.60) PRKDCATMATRSCN2ASCN10A
SCHEMBL16489091 0.70 ATR (0.60) ATRSCN2ASCN10ASMN1; SMN2POLB
SCHEMBL16489054 0.70 ATR (0.63) ATRSCN2ASCN10ASMN1; SMN2POLB
SCHEMBL10134816 0.69 JAK2 (0.53) GSK3AGSK3BSMN1; SMN2POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150051187-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2015-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051187-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 PRKDC 23/4885ATM 39/4885ATR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.